Pfizer (PFE) Receivables (2009 - 2026)
Pfizer (PFE) posted quarterly Receivables of $12.6 billion for Q1 2026, up 6.25% year-over-year from $11.8 billion in Q1 2025, and up 5.99% quarter-over-quarter from $11.9 billion in Q4 2025.
Pfizer (PFE) Receivables (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Receivables for 18 consecutive years, with $12.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 6.25% year-over-year to $12.6 billion; the TTM figure through Mar 2026 stood at $12.6 billion (up 6.25% YoY), while the FY2025 annual figure was $11.9 billion, up 3.59% from the prior year.
- Receivables advanced to $12.6 billion in Q1 2026 per PFE's latest filing, from $11.9 billion in the prior quarter.
- Across five years, Receivables topped out at $15.4 billion in Q3 2022 and bottomed at $10.2 billion in Q3 2023.
- Historically, Receivables has averaged $12.3 billion across 5 years, with a median of $11.9 billion in 2025.
- Annual changes were most pronounced in 2022 — Receivables surged 39.98% — and 2023, when it plunged 33.68%.
- Pfizer's Receivables stood at $11.0 billion in 2022, then increased by 5.61% to $11.6 billion in 2023, then retreated by 0.89% to $11.5 billion in 2024, then advanced by 3.59% to $11.9 billion in 2025, then increased by 5.99% to $12.6 billion in 2026.
- Business Quant data shows PFE's Receivables at $12.6 billion in Q1 2026, $11.9 billion in Q4 2025, and $14.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 470.06 Bn | 463.49 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 377.53 Bn | 370.39 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 302.81 Bn | 295.12 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 258.33 Bn | 253.43 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 237.17 Bn | 223.18 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 183.44 Bn | 180.26 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 160.60 Bn | 148.90 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 106.09 Bn | 101.92 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 55.33 Bn | 47.95 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 12.49 Bn |
| Mar 29, 2026 | 12.59 Bn |
| Dec 31, 2025 | 11.87 Bn |
| Sep 28, 2025 | 14.26 Bn |
| Jun 29, 2025 | 12.08 Bn |
| Mar 30, 2025 | 11.85 Bn |
| Dec 31, 2024 | 11.46 Bn |
| Sep 29, 2024 | 14.45 Bn |
| Jun 30, 2024 | 11.39 Bn |
| Mar 31, 2024 | 10.99 Bn |
| Dec 31, 2023 | 11.57 Bn |
| Jul 2, 2023 | 10.23 Bn |
| Apr 2, 2023 | 12.36 Bn |
| Dec 31, 2022 | 10.95 Bn |
| Jul 3, 2022 | 15.43 Bn |
| Apr 3, 2022 | 13.36 Bn |
| Dec 31, 2021 | 11.53 Bn |
| Oct 3, 2021 | 12.09 Bn |
| Jul 4, 2021 | 11.02 Bn |
| Apr 4, 2021 | 10.74 Bn |